New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 18, 2013
09:27 EDTRHHBY, GE, LIFE, TMOLife Technologies potential buyers could have better options, says Piper Jaffray
After Life Technologies (LIFE) said it hired two investment banks to aid in its annual strategic review, Piper Jaffray said it believes a takeover or leveraged buyout is potentially in the works. Piper said it sees several potential acquirers for Life, listing Roche (RHHBY), Thermo Fisher (TMO) and General Electric (GE) as possibly making strategic sense. However, Piper says the slower growing Research Consumables business makes up 43% of Life's revenue. As such, it believes an acquirer interested in the faster growing next-gen sequencing business has better options. Piper has a Neutral rating on shares of Life Technologies.
News For LIFE;RHHBY;TMO;GE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 16, 2015
08:04 EDTRHHBYRoche granted orphan status for lymphoma treatment
The FDA granted Roche's Genentech unit orphan status for Gazyva, its treatment of follicular lymphoma.
08:04 EDTGECon Edison Devleopment enters into agreement to procure GE energy storage system
GE (GE) announced it will supply Con Edison Development (ED) with an 8 MWh battery energy storage system in Central Valley, CA. The new storage solution will be utilizing GEs Mark VIe-based plant control system, Brilliance MW Inverters, and packaged lithium ion battery modules. As part of its expanding energy storage portfolio, this project marks the first time GE will introduce a lithium ion battery solution. The system will provide two megawatts of power over a four-hour period, and the deal includes delivery of a complete energy storage system, with associated long-term service agreements.
April 15, 2015
15:41 EDTGEGeneral Electric, Alstom may have interest in Bombardier rail unit
Subscribe for More Information
07:41 EDTTMOEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
12:05 EDTGEMarketo engagement marketing platform to integrate with LinkedIn
Marketo (MKTO) announced it will partner with LinkedIn (LNKD) on a solution that connects LinkedIn's Lead Accelerator solution with Marketo's Engagement Marketing Platform. The combination "bridges the gap between digital, social and offline channels to enable marketers to engage in relevant conversations with customers wherever they are online," the company said. GE (GE) will pioneer the joint solution, Marketo announced.
10:49 EDTGEWells Fargo sees remaining at high end of 55%-59% efficiency ratio target
Says adjusted tax rate leaves company in "mid-32%" range for rest of year. Says will look to work closely with GE Capital (GE) as it sells other businesses. Sees remaining at high end of 55%-59% efficiency ratio target. Says "optimistic" about Q2.
10:26 EDTGEWells Fargo says underlying economic expansion 'largely on track'
Subscribe for More Information
10:16 EDTTMOHigh option volume stocks
High option volume stocks: NSAM ALU CJES BIG CMRX ERIC NTAP TMO KN CIG
09:35 EDTGEActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AMZN PBR SU NFLX ALU BIDU TSLA JNJ GE
07:35 EDTGEVeracyte and General Electric join to develop genomic diagnosis solutions
Veracyte (VCYT) and GE (GE) announced a research collaboration to develop new solutions that can improve disease diagnosis. Financial and other terms were not disclosed. Veracyte will collaborate with GE Ventures, GE Healthcare, and the GE Global Research Center to explore the feasibility of combining Veracyte's genomic technology with GE Healthcare's digital imaging technology. Through the agreement, Veracyte and GE aim to identify features from raw imaging data that, when combined with genomic information, have the potential to elucidate useful, new information to further address unmet clinical needs.
06:30 EDTRHHBYRoche to seek to have cancer drug tested in 11 trials in 2015, Reuters says
Roche said it would seek to have its immunotherapy cancer drug, MPDL3280A, in 11 late stage trials by the end of 2015, aaccording to Reuters. The drug is being tested in melanoma, as well as lung, bladder, kidney, bowel and blood cancers, the news service noted. Reference Link
April 13, 2015
16:01 EDTGEOptions Update; April 13, 2015
Subscribe for More Information
10:01 EDTRHHBYRoche acquires CAPP Medical
Roche announced it has acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and industry veterans, to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA in blood.
09:34 EDTGEActive equity options trading on open
Subscribe for More Information
07:52 EDTGEBlackstone Mortgage portfolio purchase from GE a win for both, says UBS
Subscribe for More Information
07:03 EDTGEGeneral Electric risk/reward ratio positive, says Bernstein
Subscribe for More Information
06:32 EDTGEReal estate is a big part of Blackstone's business, NY Times says
Subscribe for More Information
06:09 EDTGEGE must prove that industrial business can grow reliably, WSJ reports
Subscribe for More Information
05:49 EDTGEStocks with implied volatility movement; GE SD
Subscribe for More Information
April 12, 2015
14:56 EDTGEGE investors should consider selling, Barron's says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use